Targeted Therapy Options for HER2+ Breast Cancer.
| Publicado en: | Oncology (08909091) Vol. 38; pp. 12 - 15 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | pictorial questions and answers tables/charts Journal Article |
| Publicado: |
MJH Life Sciences
2024 Supplement
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=175403462&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 175403462 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 08909091 YYT jtl: Oncology (08909091) issn: 08909091 maglogo: N pubinfo: dt: 2024 Supplement vid: 38 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 175403462 175403462 175403462 175403462 ppf: 12 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Targeted Therapy Options for HER2+ Breast Cancer. aug: au: O'Shaughnessy, Joyce McArthur, Heather Chan, Isaac Peswani, Namrata Agarwal, Ashwani K. Klemow-Reed, Dawn Osborne, Cindy affil: UT Southwestern Harold C. Simmons, Comprehensive Cancer Center, Dallas, TX sug: subj: Breast Neoplasms Therapy Oncogenes Information Resources ATP Binding Cassette Transporters Protein Kinase Inhibitors Trastuzumab Docetaxel Clinical Trials pubtype: Academic Journal doctype: pictorial questions and answers tables/charts Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|